Placenta-Derived Cell-Conditioned Medium for Animal-Free Stem Cell Culture

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for culturing human induced pluripotent stem cells using animal-derived support cells and special gels pose safety concerns and are not economically viable for mass production, as they can lead to heterologous protein contamination and high costs.

Innovation Solution

Employing a placenta-derived cell-conditioned medium (PCCM) for inducing dedifferentiation of somatic cells into induced pluripotent stem cells, using placenta-derived fibroblast-like cells isolated from the human chorionic plate, and transducing nucleic acid sequences encoding proteins like OCT4, SOX2, c-Myc, and KLF4, to create an animal-free and feeder-free culture system.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If animal-derived support cells and special gels are used for culturing human induced pluripotent stem cells, then stem cell culture can be performed, but safety problems arise due to heterologous protein contamination

Engineering Contradiction:
ImprovesafetyVSAvoidheterologous protein contamination
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and eliminates animal-derived components from the culture system by using placenta-derived fibroblast-like cells as feeder cells and preparing conditioned medium from these human cells. This removes the source of heterologous protein contamination while maintaining the necessary culture support functions, thereby resolving the safety issue without compromising stem cell culture capability.

Inventive Principle:
Principle #2Taking out (Extraction)

2Reliability

If expensive special gel is used for stem cell culture, then stem cell proliferation can be maintained, but economic viability for mass production is compromised

Engineering Contradiction:
Improvestem cell proliferationVSAvoideconomic viability
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent replaces expensive, specialized gels with a cost-effective conditioned medium prepared from placenta-derived fibroblast-like cells. These feeder cells can be easily cultured and harvested, providing a economical alternative that maintains stem cell proliferation capabilities while significantly reducing production costs for mass application.

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Ease of manufacture

If placenta-derived cell-conditioned medium is used for dedifferentiation, then animal-free and feeder-free culture is achieved, but dedifferentiation efficiency needs to be enhanced

Engineering Contradiction:
Improveanimal-free and feeder-free cultureVSAvoiddedifferentiation efficiency
Core Design Contradiction:
Ease of manufactureVSProductivity

Solution Approach 1:

The patent optimizes the conditioned medium formulation by adjusting the ratio of placenta-derived fibroblast-like cells to stem cells, controlling culture conditions (temperature, pH, gas composition), and modifying medium composition (serum-free formulations, growth factors). These parameter changes enhance dedifferentiation efficiency while maintaining the animal-free and feeder-free advantages.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach increases the efficiency of dedifferentiation into induced pluripotent stem cells, allowing for stable establishment of personalized stem cells using only human-derived products, thereby enhancing safety and economic viability.

Implementation Method 1

proliferation and differentiation of pluripotent stem cells can be performed by the mechanism of CXCR2 which is a chemokine receptor

Methodology Applied
Scientific EffectChemokine receptor mechanism (CXCR2):

Data Source

PatentEP3730605B1Placenta-derived cell-conditioned medium for inducing dedifferentiation from somatic cell to induced pluripotent stem cell and dedifferentiation-inducing method using same
Publication Date: 2023.08.23 KOREA UNIV RES & BUSINESS FOUND
  • EP3730605B1 patent drawingFigure 5b
  • EP3730605B1 patent drawingFigure 5c
  • EP3730605B1 patent drawingFigure 6a

AI summary

The present disclosure relates to a placenta-derived cell-conditioned medium for inducing dedifferentiation into induced pluripotent stem cells from somatic cells and a method for inducing dedifferentiation using the same. When the placenta-derived cell-conditioned medium for inducing dedifferentiation according to the present disclosure is employed, personalized dedifferentiation stem cells can be stably established using a medium composed of human-derived products only. Provision of a human placenta-derived environment similarly represents an in vivo environment and allows the production of a cell therapy product without problems for clinical application.